Search Within

MSK Grad Students

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (519)
  2. Journal Article (329)
  3. Review (40)
  4. Miscellaneous (16)
  5. Research Letter (15)
  6. Editorial (14)
  7. Correspondence (12)
  8. Conference Paper (4)
  9. Book Section (3)
  10. Guidelines (3)
Groups
  1. CTCR Scholars (955)
  2. Master of Science in Clinical and Translational Cancer Research (955)
  3. Department of Medicine (853)
  4. Hematologic Malignancies, Division of (651)
  5. Center for Hematologic Malignancies (630)
  6. Survivorship Research (578)

More Groups

People
  1. Sergio Giralt (378)
  2. Miguel-Angel Perales (356)
  3. Parastoo Dahi (294)
  4. Sean Devlin (265)
  5. Doris Ponce (254)
  6. Roni Tamari (208)

More People

Years
  1. 2025 (41)
  2. 2024 (109)
  3. 2023 (140)
  4. 2022 (121)
  5. 2021 (104)
  6. 2020 (119)

More Years

Publications
  1. Blood (191)
  2. Biology of Blood and Marrow Transplantation (153)
  3. Journal of Clinical Oncology (79)
  4. Annals of Surgical Oncology (78)
  5. Bone Marrow Transplantation (55)
  6. Transplantation and Cellular Therapy (42)

More Publications

Publishers
  1. American Society of Hematology (223)
  2. Elsevier Inc. (219)
  3. Springer (90)
  4. American Society of Clinical Oncology (87)
  5. Nature Publishing Group (82)
  6. American Association for Cancer Research (29)

More Publishers

Results (955)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G. S.; Kim, H. T.; O'Connor, S.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; El-Jawahri, A.; McAfee, S.; Hem, J.; Lozano, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL
    Meeting Abstract

    Merryman, R. W.; Rhoades, J.; Xiong, K.; Antel, K.; An, H. H.; Redd, R. A.; McDonough, M. M.; Guerrero, L.; Crnjac, A.; Sridhar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of investigational microbiome therapeutic SER-155 on pathogen domination: Initial results from a phase 1b study in adults undergoing allogeneic hematopoietic cell transplantation (HCT)
    Meeting Abstract

    Peled, J. U.; van den Brink, M. R. M.; Ponce, D. M.; Kosuri, S.; Khera, N.; DeFilipp, Z.; Tejura, B.; Lichter, D. I.; Lombardo, M. J.; Wortman, J. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Topical ruxolitinib for chronic cutaneous GvHD: Promising results of a phase 2 clinical trial
    Meeting Abstract

    Markova, A.; Papadopoulos, E. B.; Dusza, S.; Ostojić, J.; Ai, R.; Maier, T.; Lacouture, M.; Tamari, R.; Gyurkocza, B.; Shaffer, B. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • High progression-free survival with low relapse rates after double-unit cord blood transplantation in patients with high-risk AML
    Meeting Abstract

    Politikos, I.; Fingrut, W. B.; Brown, S.; Chinapen, S.; Quach, S.; Dahi, P. B.; Gyurkocza, B.; Jakubowski, A. A.; Papadopoulos, E. B.; Ponce, D. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TNC/Kg and CD34+/Kg cell dose impact on patient engraftment after allogeneic transplant with conventional bone marrow; Better predictability of graft content needed
    Meeting Abstract

    Davis, E.; Feuer, E.; Rapoport, C.; Lobaugh, S.; Devlin, S. M.; Archer, A.; Chinapen, S.; Federman, J.; Kelly, A.; Klein, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dynamics of radiomic features following bridging therapy determine CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J. R.; Devlin, S. M.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Wills, B.; Tomas, A. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • 18F-FDG PET/CT imaging biomarkers for car-T cell therapy outcomes in large-B-cell lymphoma
    Meeting Abstract

    Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M.; Luttwak, E.; more...
    Blood (2023)

    Fulltext@MSK | Save